Abstracts tagged "Allopurinol and gout"

Abstract Number: 359 • 2019 ACR/ARP Annual Meeting
Impact of Hospital Admissions on Adherence to Allopurinol Therapy After Discharge
Nicholas Lebedoff¹, Andrea Barker ², Curry L. Koening ³, Trevor Jones ⁴, Richard Rose ⁴, Peter Yarbrough ⁴ and Michael Battistone ⁵, ¹University of Utah, Salt Lake City, ²Salt Lake City Veterans Affairs Medical Center & University of Utah, North Salt Lake, UT, ³University of Utah Hospital, Salt Lake City, UT, ⁴Salt Lake City Veterans Affairs Medical Center & University of Utah, Salt Lake City, ⁵Salt Lake City Veterans Affairs Medical Center & University of Utah, Salt Lake City, UT
Background/Purpose: Gout is a common disease with effective medical therapies, yet many cases are complicated by providers’ hesitancy to prescribe an adequate dose of urate-lowering…
Abstract Number: 1266 • 2018 ACR/ARHP Annual Meeting
ABCG2 rs2231142 Q141K and Oxypurinol Concentration in People with Gout Receiving Allopurinol
Lisa K. Stamp¹, Mary Wallace², Rebecca Roberts³, Christopher Frampton¹, Jeffrey Miner⁴, Tony R. Merriman³ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Surgical Sciences, University of Otago, Dunedin, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴Viscentio Bio, San Diego, CA, ⁵University of Auckland, Auckland, New Zealand
Background/Purpose: Association of ABCG2 Q141K (p.141Lys) with poor urate-lowering response to allopurinol has been reported although the mechanism is unclear. ABCG2 has been reported to…
Abstract Number: 2229 • 2018 ACR/ARHP Annual Meeting
Can We Predict Inadequate Response to Allopurinol Dose Escalation? Analysis of a Randomized Controlled Trial
Lisa K. Stamp¹, Peter T. Chapman², Murray Barclay³, Anne Horne⁴, Christopher Frampton¹, Paul Tan⁵, Jill Drake⁶ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Medicine, University of Otago, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: The two most common causes of inadequate serum urate (SU) lowering with allopurinol are low adherence and under-dosing. Those who are adherent, but do…
Abstract Number: 2230 • 2018 ACR/ARHP Annual Meeting
Serum Urate Levels in People with Gout on Dialysis – Are We Achieving Treatment Targets?
Estella Yeo¹, Suetonia Palmer², Peter T. Chapman³, Christopher Frampton⁴ and Lisa K. Stamp⁴, ¹Canterbury District Health Board, Christchurch, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand, ³Christchurch Hospital, Christchurch, New Zealand, ⁴University of Otago, Christchurch, New Zealand
Background/Purpose: To explore the number of patients on haemodialysis (HD) or peritoneal dialysis (PD) with gout in Canterbury and to determine how many were receiving…
Abstract Number: 1105 • 2017 ACR/ARHP Annual Meeting
Allopurinol Dose Escalation to Achieve Serum Urate below 6mg/Dl: An Open Label Extension Study
Lisa K. Stamp¹, Peter T. Chapman², Murray Barclay³, Anne Horne⁴, Christopher Frampton¹, Paul Tan⁵, Jill Drake⁶ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Medicine, University of Otago, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: Allopurinol at higher than CrCL based doses remains controversial due to concerns over increased risk of adverse events (AE). A recent 12month randomized controlled…
Abstract Number: 1138 • 2017 ACR/ARHP Annual Meeting
Investigation on Allele Frequency of Rs3117583 and Rs9263726 in Patients with Hyperuricemia or Gout
Xiaomin Li¹, Qiujing Wei², Naomi Schlesinger³ and Jieruo Gu², ¹Rheumatology, Third affiliated hospital of Sun Yat-sen University, Guangzhou, China, ²Rheumatology, Third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ³Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Allopurinol, effectively regulates and controls serum uric acid levels but may cause allopurinol-induced life-threating severe cutaneous adverse reaction (SCAR). Previous studies reported that single…
Abstract Number: 3078 • 2015 ACR/ARHP Annual Meeting
ABCG2 rs2231142 predicts Poor Response to Allopurinol in Patients with Gout
Lisa K. Stamp¹, Mary Wallace², Tony R. Merriman³, Amanda Phipps-Green⁴, Ruth Topless^4,5, Jill Drake⁶, Paul Tan⁷, Nicola Dalbeth⁸ and Rebecca Roberts⁴, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Surgical Sciences, University of Otago, Dunedin, New Zealand, ³Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ⁴University of Otago, Dunedin, New Zealand, ⁵Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁶Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand, ⁷University of Auckland, Auckland, New Zealand, ⁸Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Many patients fail to reach target serum urate (SU) on allopurinol. Although the most common causes of inadequate response are non-adherence and low dosing…